MNOV Overview
Upcoming Projects (MNOV)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MNOV)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (MNOV)
-
Discussing MediciNova’s MN-166 for the treatment of ARDS, sepsis, and cytokine release syndrome, following IV results
Ticker: MNOV
Execute By: Feb 28, 2023 -
Understanding the results from Medicinova’s SPRINT-MS Phase 2b Trial of MN-166 in Progressive MS
Ticker: MNOV
Execute By: Feb 14, 2018
Upcoming & Overdue Catalysts (MNOV)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (MNOV)
-
Phase 2b data of MN-166 for Progressive multiple sclerosis (progressive MS) due Oct 28 2017
Ticker: MNOV
Occurred on: Oct 26, 2017 -
MediciNova's lead product candidate slows progression of ALS in mid-stage study
Ticker: MNOV
Occurred on: Apr 20, 2016 -
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis
Ticker: MNOV
Occurred on: Jan 27, 2016
Strategic Initiatives (MNOV)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
